Back to Agenda
Session 3C: New Approaches in the Development of Immune Stimulatory Oligonucleotides in Oncology
Session Chair(s)
Arthur M. Krieg, MD
CEO and CSO, Checkmate Pharmaceuticals, United States
The innate immune system has evolved multiple different receptors for the detection of viral or bacterial RNA and DNA including several Toll-like receptors (TLR), the RIG-I family of helicases, cGAS, and others. These receptors trigger both T cell and B cell adaptive immune responses that are capable of killing infected host cells. Synthetic nucleic acids that activate several different innate immune receptors are in clinical development for the purpose of triggering innate immune resposnes against tumor antigens in subjects with cancer.
Learning Objective :
Speaker(s)
Emily Place, PHD, MPH
Senior Consultant, Aclairo Pharmaceutical Development Group, United States
Session Co-Chair
Arthur M. Krieg, MD
CEO and CSO, Checkmate Pharmaceuticals, United States
Making “Cold” Tumors “Hot” with Intratumoral Injections of a CpG-A Oligonucleotide Packaged in a VLP
Jonathan Yingling
Senior Vice President, Early Developement, Idera, United States
Exploiting the TLR9 Pathway to Overcome Tumor Immune Ignorance
Matthias Miller, PHD
Project Manager, BioNTech RNA Pharmaceuticals GmbH, Germany
Cancer Immunotherapy: Individualized mRNA-Based Vaccines for the Treatment of Cancer
Panel Discussion
, All Session Speakers, United States
Have an account?